EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A

Taiwanese biosimilar developer EirGenix Inc. (TWSE: 6589) has expanded its strategic partnership with Swiss biopharmaceutical leader Sandoz AG (SIX: SDZ, OTCQX: SDZNY) through a global exclusive licensing agreement for its second HER2-targeting biosimilar candidate, EG1206A. The pertuzumab biosimilar, developed as an alternative to Roche’s Perjeta, will be commercialized across all territories except for select Asian markets such as Taiwan, Mainland China, Japan, South Korea, and several Southeast Asian countries.

The agreement grants Sandoz commercialization rights while keeping product development, manufacturing, and supply under the control of EirGenix. In return, EirGenix will receive up to USD 152 million in upfront and milestone payments, alongside a share of profits and potential sales-based performance incentives once EG1206A enters licensed markets.

The announcement further solidifies the collaborative trajectory between EirGenix and Sandoz following their 2022 deal for EG12014, a trastuzumab biosimilar that has already received regulatory approval from the European Commission and remains under review by the U.S. Food and Drug Administration. The latest deal marks EirGenix’s continued push to establish itself as a major player in the global biosimilar arena, especially within the competitive oncology segment.

How does EG1206A strengthen EirGenix’s biosimilar footprint and global pipeline credibility?

The EG1206A agreement is not just a commercial win but a validation of EirGenix’s technical capabilities in reverse-engineering complex biologics and accelerating timelines through regulatory optimization. The pertuzumab biosimilar has already completed its pharmacokinetic clinical study and recently received favorable feedback from both the U.S. Food and Drug Administration and the European Medicines Agency. These agencies confirmed that EG1206A qualifies for an abbreviated development pathway, allowing it to bypass full Phase III comparative efficacy trials.

This waiver is a critical competitive advantage. By reducing clinical burden and capital costs, EirGenix can bring EG1206A to market faster than traditional biosimilar development models. For Sandoz, this translates into earlier commercial entry with lower R&D investment, making the asset particularly attractive in the face of mounting cost pressures across global healthcare systems.

The licensing deal also highlights the increasing acceptance by regulators of pharmacokinetic and analytical similarity data as sufficient for biosimilar approval in certain therapeutic categories, especially when the mechanism of action and safety profiles are well-characterized, as is the case with pertuzumab.

Why is the HER2-positive breast cancer segment ripe for biosimilar expansion in 2025?

HER2-positive breast cancer accounts for nearly 20 percent of all breast cancer cases, which globally total around 2.3 million patients annually. This subset has historically been treated using a dual antibody approach that combines trastuzumab and pertuzumab. This regimen, marketed by Roche under the brands Herceptin and Perjeta, has become the gold standard in both early-stage and metastatic disease.

However, with global healthcare budgets under increasing pressure, biosimilars like EG12014 and EG1206A are poised to offer clinically equivalent treatment at lower costs, expanding access for public and private payers alike. Roche’s 2024 annual report confirmed that Perjeta generated CHF 3.62 billion (approximately USD 4 billion) in sales, underscoring the commercial opportunity that biosimilars can tap into as originator patents lapse.

Recent clinical updates further reinforce the therapeutic relevance of pertuzumab. Ongoing studies suggest that newer combinations involving trastuzumab deruxtecan (Enhertu) may redefine the treatment landscape in metastatic settings, but the foundational role of pertuzumab in first-line treatment remains intact. This backdrop positions EG1206A as a strong candidate to capture significant volume in geographies where biosimilar substitution is accelerating.

What does this agreement reveal about EirGenix’s evolving commercial and R&D strategy?

The second licensing agreement with Sandoz signals EirGenix’s shift from being a regional player to a globally visible biosimilar innovator. With EG12014 already approved in Europe and under regulatory review in the United States, the addition of EG1206A strengthens its HER2-targeted oncology portfolio and diversifies revenue potential.

EirGenix has adopted a hybrid strategy of developing its own pipeline while also offering CDMO services to other pharmaceutical companies. Its two commercial-scale production lines in Zhubei, Taiwan, have become an operational asset in courting global partnerships. The company’s expertise in reverse engineering, combined with a growing regulatory track record, has attracted increased attention from multinational firms seeking efficient biosimilar development partners.

Beyond EG12014 and EG1206A, EirGenix is working on four additional HER2-targeting antibodies, indicating a deliberate focus on building depth within a single high-value therapeutic category. Analysts believe this clustering approach may provide EirGenix with cost advantages, manufacturing synergies, and scientific know-how that can be leveraged across the entire HER2 pipeline.

How does Sandoz benefit from deepening its partnership with EirGenix?

Sandoz’s decision to expand its partnership with EirGenix aligns with its global strategy of pioneering access to affordable biologics. As the originator exclusivity for Perjeta wanes, entering the pertuzumab biosimilar race early provides Sandoz with a competitive foothold in oncology. Having previously partnered with EirGenix on EG12014, Sandoz is already familiar with the company’s manufacturing standards, regulatory alignment, and product development timelines.

Sandoz has a long legacy of biosimilar leadership. The company introduced the world’s first biosimilar in 2006 and delivered over 900 million patient treatments in 2024 alone. With a portfolio of 1,300 products and net sales of USD 10.4 billion in 2024, Sandoz continues to expand its presence in high-margin specialty segments. Oncology is one of its strategic focus areas, and the addition of a pertuzumab biosimilar further differentiates its offerings from competitors like Viatris, Biocon Biologics, and Amgen.

Industry observers tracking biosimilar competition see the EG1206A deal as Sandoz doubling down on oncology with a trusted partner, rather than pursuing asset acquisition or in-house development. This approach de-risks capital allocation while still enabling aggressive market entry, especially in Europe and South America where biosimilar penetration is highest.

What are the financial and institutional implications of this deal for EirGenix and investors?

While specific upfront payment details were not disclosed, the total value of the deal, up to USD 152 million, indicates a sizable financial runway for EirGenix heading into 2026. The deal structure includes milestone payments linked to regulatory approvals and market launches, as well as profit-sharing and additional sales incentives based on performance.

Analysts covering Taiwan’s biotech sector believe this licensing agreement will materially improve EirGenix’s revenue visibility and accelerate its cash flows over the next two years. With EG12014 already generating early returns and EG1206A now de-risked from a regulatory standpoint, the dual HER2 biosimilar platform offers EirGenix a base for recurring income, especially as manufacturing ramps up at scale.

Investor interest in biosimilar CDMOs has grown in tandem with the global shift toward cost-effective biologics. EirGenix, with its dual identity as a product innovator and manufacturing partner, is increasingly viewed as a hybrid model worth tracking. The company’s global ambitions and regulatory progress may also lay the groundwork for future capital raises or even dual listings to attract foreign institutional interest.

What signals should industry watchers and biosimilar stakeholders monitor going forward?

The next 12 to 18 months will be critical in determining the commercial success of EG1206A. Key milestones to watch include regulatory submissions in major territories, commercialization timelines from Sandoz, and updates on real-world manufacturing capacity in Zhubei. Any additional licensing agreements for the remaining HER2 pipeline assets could further amplify EirGenix’s visibility.

From a competitive standpoint, market watchers will be observing how Roche adapts to increasing biosimilar competition and whether Sandoz and EirGenix can capture formulary share in highly regulated environments like the European Union, Canada, and Latin America.

Additionally, the continued expansion of biosimilar waivers and streamlined regulatory pathways by the U.S. Food and Drug Administration and the European Medicines Agency could provide further momentum to companies operating with lean development timelines, such as EirGenix.

With the biosimilar market forecasted to exceed USD 60 billion by 2030, EirGenix is positioning itself not just as a participant but as a platform builder within oncology’s most durable biologics segment.

Key takeaways from EirGenix’s EG1206A licensing agreement with Sandoz

• EirGenix Inc. signed a global exclusive licensing deal with Sandoz AG for EG1206A, its pertuzumab biosimilar to Roche’s Perjeta.
• The agreement covers all territories except Taiwan, Mainland China, Japan, South Korea, and several Southeast Asian markets.
• The deal is valued at up to USD 152 million in upfront and milestone payments, with additional profit-sharing and sales incentives.
• EG1206A has completed its pharmacokinetic clinical study and secured an abbreviated approval pathway from the U.S. Food and Drug Administration and the European Medicines Agency, waiving Phase III efficacy trials.
• The partnership builds on EirGenix and Sandoz’s earlier collaboration on EG12014, a trastuzumab biosimilar already approved in Europe.
• EG1206A targets HER2-positive breast cancer, which accounts for around 20% of the 2.3 million global breast cancer cases.
• Roche’s Perjeta generated USD 4 billion in global sales in 2024, highlighting the commercial potential for biosimilar challengers.
• EirGenix will retain responsibility for development, manufacturing, and global supply of EG1206A, while Sandoz leads commercialization.
• The Taiwanese biotech firm is advancing four more HER2-targeted biosimilars and scaling up CDMO services at its Zhubei facility.
• Investors are watching EirGenix for future licensing activity, manufacturing scale-up, and additional FDA or EMA regulatory milestones.